Blockade of the Angiotensin II Type 1 Receptor Stabilizes Atherosclerotic Plaques in Humans by Inhibiting Prostaglandin E2-Dependent Matrix Metalloproteinase Activity

Circulation

Volumn 109, Issue 12, 2004, Pages 1482-1488

  Cipollone, Francesco ^a   Fazia, Maria ^a   Iezzi, Annalisa ^a   Pini, Barbara ^a   Cuccurullo, Chiara ^a   Zucchelli, Mirco ^a   De Cesare, Domenico ^a   Ucchino, Sante ^a   Spigonardo, Francesco ^a   De Luca, Mariella ^a   Muraro, Raffaella ^a   Bei, Roberto ^b   Bucci, Marco ^a   Cuccurullo, Franco ^a   Mezzetti, Andrea ^a,c  

^a UNIVERSITY OF CHIETI   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c Annunziata   (Italy)

Author keywords

Inflammation; Metalloproteinases; Plaque; Prostaglandins

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ANGIOTENSIN 1 RECEPTOR; CD3 ANTIGEN; CD68 ANTIGEN; CHLORTALIDONE; COLLAGEN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; HLA DR ANTIGEN; IRBESARTAN; MATRIX METALLOPROTEINASE; MESSENGER RNA; PROSTAGLANDIN E2;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATHEROSCLEROTIC PLAQUE; CAROTID ENDARTERECTOMY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; HYPERTENSION; IMMUNOHISTOCHEMISTRY; INTERNAL CAROTID ARTERY OCCLUSION; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; MONOCYTE; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS INHIBITION; RANDOMIZED CONTROLLED TRIAL; RECEPTOR BLOCKING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

AGED; ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BIPHENYL COMPOUNDS; CAROTID ARTERY, INTERNAL; CAROTID STENOSIS; CHLORTHALIDONE; COLLAGEN; COMBINED MODALITY THERAPY; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DEPRESSION, CHEMICAL; DINOPROSTONE; ENDARTERECTOMY, CAROTID; ENZYME INDUCTION; EXTRACELLULAR MATRIX; FEMALE; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION; INTRAMOLECULAR OXIDOREDUCTASES; ISOENZYMES; MACROPHAGES; MALE; MATRIX METALLOPROTEINASES; MEMBRANE PROTEINS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROTEASE INHIBITORS; RUPTURE, SPONTANEOUS; TETRAZOLES;

EID: 12144289317     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000121735.52471.AC     Document Type: Article

References (25)

1. Daugherty A, Manning MW, Cassis LA. Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J Clin Invest. 2000;105;1605-1612.
2. HOPE Study Investigators. Effects of an Ang-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342:145-153.
3. Wing LMH, Reid CM, Ryan P, et al. Second Australian National Blood Pressure Study: a comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med. 2003;348:583-592.
4. Dahlof B, Devereux RB, Kjeldsen S, et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint Reduction in Hypertension Study (LIFE): a randomized trial against atenolol. Lancet. 2002;359:995-1003.
5. Schmidt-Ott KM, Kagiyama S, Philips MI. The multiple actions of Ang in atherosclerosis. Regul Pept. 2000;93:65-77.
6. Ohnaka K, Numaguchi K, Yamakawa T, et al. Induction of cyclooxygenase-2 by angiotensin II in cultured rat vascular smooth muscle cells. Hypertension. 2000;35:68-75.
7. Brilla CG, Zhou G, Rupp H, et al. Role of angiotensin II and prostaglandin E2 in regulating cardiac fibroblast collagen turnover. Am J Cardiol. 1995;76:8D-13D.
8. Cipollone F, Prontera C, Pini B, et al. Overexpression of functionally coupled cyclooxygenase-2 and prostaglandin E synthase in symptomatic atherosclerotic plaques as a basis of prostaglandin E(2)-dependent plaque instability. Circulation. 2001;104:921-927.
9. Cipollone F, Fazia M, lezzi A, et al. Suppression of the functionally coupled cyclooxygenase-2/PGE synthase as a basis of simvastat-independent plaque stabilization in humans. Circulation. 2003;107:1479-1485.
10. Hoshida S, Kato J, Nishino M, et al. Increased angiotensin-converting enzyme activity in coronary artery specimens from patients with acute coronary syndromes. Circulation. 2001;103:630-633.
11. Schieffer B, Schieffer E, Hilfiker-Kleiner D, et al. Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability. Circulation. 2000;101:1372-1378.
12. 2 in lipopolysaccharide-stimulated rat peritoneal macrophages. Biochem Biophys Res Commun. 1997;230:110-114.
13. Cazaubon C, Gougat J, Bousquet F, et al. Pharmacological characterization of SR47436, a new nonpeptide AT1 subtype angiotensin II receptor antagonist. J Pharmacol Exp Ther. 1993;265:826-834.
14. North American Symptomatic Carotid Endarterectomy Trial: methods, patient characteristics, and progress. Stroke. 1991;22:711-720.
15. de Vries HE, Buchner B, van Berkel TJ, et al. Specific interaction of oxidized low-density lipoprotein with macrophage-derived foam cells isolated from rabbit atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 1999;19:638-645.
16. Woessner JF Jr. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J. 1991;5:2145-2154.
17. Burleigh ME, Babaev VR, Oates JA, et al. Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice. Circulation. 2002;105:1816-1823.
18. 2. Science. 2002;296:539-541.
19. Belton O, Byrne D, Kearney D, et al. Cyclooxygenase-1- and -2-dependent prostacyclin formation in patients with atherosclerosis. Circulation. 2000;102:840-845.
20. Marx N, Schönbeck U, Lazar MA, et al. Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ Res. 1998;83:1097-1103.
21. Strawn WB, Chappell MC, Dean RH, et al. Inhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemia. Circulation. 2000;101:1586-1593.
22. Navalkar S, Parthasarathy S, Santanam N, et al. Irbesartan, an angiotensin type 1 receptor inhibitor, regulates markers of inflammation in patients with premature atherosclerosis. J Am Coll Cardiol. 2001;37:440-444.
23. 1 receptor function and density in hypercholesterolemic men. Circulation. 1999;100:2131-2134.
24. Horiuchi M, Cui TX, Li Z, et al. Fluvastatin enhances the inhibitory effects of a selective angiotensin II type 1 receptor blocker, valsartan, on vascular neointimal formation. Circulation. 2003;107:106-112.
25. ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981-2997.